Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

July 14, 2009

Primary Completion Date

April 26, 2011

Study Completion Date

March 21, 2012

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Herpes Zoster Vaccine 1437173A

Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.

BIOLOGICAL

Placebo vaccine (saline)

1 or 3 doses of Placebo (saline) injected intramuscularly.

Trial Locations (11)

10065

GSK Investigational Site, New York

19104

GSK Investigational Site, Philadelphia

27599

GSK Investigational Site, Chapel Hill

27705

GSK Investigational Site, Durham

44195

GSK Investigational Site, Cleveland

55455

GSK Investigational Site, Minneota

55905

GSK Investigational Site, Rochester

72205

GSK Investigational Site, Little Rock

91010

GSK Investigational Site, Duarte

94143

GSK Investigational Site, San Francisco

02115

GSK Investigational Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY